Winners of Digital RESI June 2021 Innovator’s Pitch Challenge (IPC)

17 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Digital Redefining Early Stage Investments (RESI) June ended on a high note last week, again providing a valuable platform for early-stage life science companies and investors/strategic partners to connect and start dialogue.

This RESI also featured the largest number of Innovator’s Pitch Challenge companies, with almost fifty companies participating. Each company was assigned to one of ten live Q&A sessions featuring investors and industry partners, based on sector/technology.

Attendees voted for their favorite companies throughout the three days of the conference. Check out the winners below!

1st Place – Throne Biotechnologies

Throne is an American therapeutics company aimed at commercializing a novel stem cell technology that can fundamentally reverse diabetes, alopecia areata and other autoimmune diseases through immune education. The patented technology is recognized as the leading “practical cure project” for type 1 diabetes among 594 global projects (JDCA 2020). Stem Cell Educator therapy is a single dialysis-like treatment that fundamentally “resets” a patient’s immune system and corrects the underlying autoimmunity. 200+ patients between the ages of 3 and 70 have been treated in 10 years of clinical research in Spain, China, and US. 70% of type 1 and type 2 diabetic patients demonstrated clinical efficacy. Many patients reduced insulin dosing and some have become insulin independent. This technology has been successfully tried in more than 10 autoimmune diseases including alopecia, lupus, fibrosis, and scleroderma. This therapy is ready to use and is approved to begin three FDA phase 2 clinical trials (type 1 diabetes, alopecia areata, COVID-19). Throne is looking to raise $5M to complete US FDA phase 2 through to commercialization. Throne is open to partnerships, joint ventures, investments, and license arrangements.

2nd Place – Praetego

Praetego is a pre-clinical stage pharmaceutical company with a mission to improve the health and longevity of diabetic patients. Praetego is developing novel small molecules (Amadorins) to alleviate serious diabetic complications, starting with peripheral neuropathy. Amadorins are first-in-class molecules able to inhibit a primary driver of diabetic microvascular disease and are derived from a clinically proven prototype.

3rd Place – Nano PharmaSolutions

A proprietary drug delivery nanotechnology that generates poorly soluble drugs as nanoparticles for better bioavailability. Our NanoTransformer(TM) technology can generate drug nanoparticles through phase transfer method without using any chemicals or solvent. We work with (1) preclinical stage drug developers for animal study formulations and (2) innovative generic companies for generic nanodrug development. We are at revenue stage and our revenue forecast is $150M in 2026 (our target exit time frame).

Congratulations to each of the winners, who have received free tickets to future RESI conferences to boost their fundraising efforts. Thank you to all finalists, judges, and attendees who make the IPC an exciting and powerful part of RESI! Interested in joining a future IPC? Applications are open for RESI Partnering Week September, featuring three separate RESI conferences! Select the logos below to learn more!

Apply for RESI IPC
Sept.13-15
Apply for RESI AI IPC
Sept.16-17
Apply for RESI Longevity IPC
Sept.16-17

Super early bird rates apply until July 9. Sign up now to save $100!

Panels at RESI Partnering Week September 13-17, 2021

17 Jun

By Rory McCann, Marketing Manager & Conference Producer, LSN

RESI Partnering Week returns September 13-17 and attendees can save $100 when they register by July 9! RESI Partnering Week is a five-day digital partnering experience connecting early-stage entrepreneurs in drugs, devices, diagnostics, and digital health with active investors who are a fit for their product and stage of development.

The RESI creators at Life Science Nation (LSN) understand that partnering is a multi-faceted process that takes time and commitment to yield fruitful relationships that turn into strategic partnerships. We offer several programs for attendees to take advantage of in order to optimize their experience, including our interactive panels that feature prominent life science and healthcare investors, as well as fundraising executives with their own tales from the road.

resi-sept-logo

  • Angels & Family Offices
  • Asia Cross Border
  • Big Pharma
  • Corporate VC
  • Medical Devices
  • Mental & Behavioral Health
  • Seed Funds
  • Tales from the Road

resi-ai-sept

  • Healthcare Communications
  • Reproductive Wellness
  • Healthcare Systems and Infrastructure
  • Accelerated Pharmaceutical Development
  • Diagnostic Wearables
  • Precision Medicine

resi-longevity-sept

  • Social Isolation & Loneliness
  • Health & Home Care
  • Medical Accountability & Adherence
  • Sensory Wellness

Contact us to learn more about RESI Partnering Week and how we can tailor the experience to meet your partnering needs.

For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
International & MA (USA) West Coast (USA) East Coast (USA) & Canada Midwest (USA)
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!
Antoinette Lowre
Manager of Business Development
Schedule a call with me!

Amarex’s Success at RESI’s Service Provider Showcase

17 Jun

By Elizabeth Murphy, Manager of Business Development, LSN

Service Provider Showcase participant, Amarex Clinical Research joined Digital RESI on June 8-10 by hosting a dynamic workshop on Expediting U.S. FDA Submissions/Trial Initiations and Acceptance of Foreign Data by the U.S. FDA. The Amarex team put on a well-attended workshop helping early-stage entrepreneurs navigate the often-complicated processes working with the FDA. Of their experience with Digital RESI, the team said, “This virtual conference provided Amarex a fantastic opportunity to present in front of leading venture capitalists and pharma/biotech startups on top strategies to get products through the FDA clinical trials approval process. “

As a sponsor of the event, Amarex’s content received prominent placement on the 3-day event agenda, but also the partnering platform. Newcomers to the Digital RESI experience, the Amarex team said, “RESI’s platform provides the life sciences industry with innovative ways to network through their partnering program, allowing our team members to build new relationships with key executives. We look forward to participating in future RESI events.”

Digital RESI returns in September, as a part of RESI Partnering Week, alongside RESI AI and RESI Longevity. Learn more about the 5-day partnering experience and how your organization can take part in the sponsorship opportunities, reach more clients, and help them reach their goals.

For a demo, or to see how many investors in our a database are interested in your product, feel free to schedule a time that works best for you via LSN BD team’s Calendly link below.
International & MA (USA) West Coast (USA) East Coast (USA) & Canada Midwest (USA)
Greg Mannix
Vice President International Business Development
Schedule a call with me!
Candice He
Director of Pacific Region & Global Investment Strategist
Schedule a call with me!
Elizabeth Murphy
Manager of Business Development
Schedule a call with me!
Antoinette Lowre
Manager of Business Development
Schedule a call with me!

Hot Investor Mandate: Corporate Venture Funds of Large Healthcare Insurance Company Strategically Invests Up to $20M in Devices, Diagnostics, Digital Health

17 Jun

An investment firm based in the USA manages corporate venture funds of a large health system and  looks to invest in companies of strategic interest to its major health plan investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.

Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.

The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Seed Fund Connected to Major China VC Invests in Companies with China Market Potential, Open to All Sectors Within Life Sciences

17 Jun

A seed fund in collaboration with a major China venture capital firm manages over $1B has both USD funds and CNY funds. The firm has invested in over 700 portfolio companies, including over 60 life science companies. While open to growth stage companies, the firm prefers to get involved as early as possible, and ideally be the first institutional investor for its portfolio company. Initial sizes of investment can largely vary, but a typical allocation size is between $1 MM to $2 MM. The firm is very entrepreneurs friendly, and invests in companies across the globe.

The firm has a general interest in Therapeutics, Digital Health, MedTech, and Diagnostics.

The firm believes that great businesses start with exceptional founding teams and values the management team of a start-up more than anything else. The firm prefers companies with a Chinese angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Fund is Most Interested in Early-Stage Therapeutics Opportunities With Broad Interests in Other Sectors, Invests Up to $20M

17 Jun

A USA based fund supports and advances life science technologies from early development through clinical proof-of-concept. The firm’s experienced leadership team works with scientists and entrepreneurs to provide active mentorship, financing solutions and operational guidance to increase the probability of success in early drug development.

The size of initial seed investment can range from $0.5M to $1.5M. The subsequent Series A investments will be sized to get through preclinical and IND-enabling work and/or through a clinical development study and can range between $8M-$20M, with flexibility to syndicate with investors for larger rounds. For more mature companies that don’t require a seed round or the need to do complete activities/studies prior to a Series A, the fund can invest directly as a Series A investment along with participation in related Series B investments.  The firm is open to global opportunities.

The firm supports opportunities across all therapeutic areas and drug modalities (small molecule, peptides, antibodies, genetic technologies, cell therapy, etc.).  Additionally, the firm is open to technologies beyond drug therapeutics, including medical devices, diagnostics and emerging healthtech opportunities (digital health, telemedicine, enabling technologies utilizing AI/ML, etc.). Founder and entrepreneur friendly, supportive of first-time CEOs, and works side by side to drive value inflections with the goal to optimize program development and successful outcomes.

The firm is open to working with all types of management teams, including first time entrepreneurs. The firm works hands-on with its portfolio companies by bringing a powerful network, access to resources and expertise to support their growth. The firm prefers to lead but is open to participating with likeminded co-investors to form syndicates.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Fund With Ties to China Seeks Global Early-Stage Drugs, Devices, Diagnostics, and Digital Health, with Focus in North America

17 Jun

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: